http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
각종 간질환 환자에서 HPLC 를 이용한 요중 Neopterin 치의 임상적 의의
심대석(Dae Seok Shim),이옥재(Ok Jae Lee),김영채(Young Chai Kim),하우송(Woo Song Ha),박순태(Soon Tae Park) 대한내과학회 1996 대한내과학회지 Vol.51 No.5
N/A Objectives: In vivo, increased level of urinary neopterin was demonstrated in patients with viral, bacterial infection, autoimmune disease, malignancy, cellular graft rejection in transplantation, and AIDS. Increased serum and urinary neopterin levels have been observed in patients with acute hepatitis, chronic hepatitis, and liver cirrhosis. The aim of this study is to evaluate the clinical significance of urinary neopterin in patients with various liver diseases. Methods: Urinary levels of neopterin were measured by HPLC (High Performance Liquid Chromatography) in 66 patients with various liver disease and 12 healthy controls. Results: 1) Urinary neopterin level increased significantly in AH (1217.82±380.97 μmol/mol creatinine), CPH (263.15±70.48 μmol/mol Cr), CAH (307.93±100.65 μmol/mol Cr), LC (276.67±66.67 μmol/mol Cr), HCC (1003.83±289.06 μmol/mol Cr) than control group (136.63±59.05 μmol/mol Cr) (p<0.001). However, urinary neopterin level in ASC or ALD was not significantly different from control group. 2) In AH, urinary neopterin levels significantly correlated with serum AST (r=0.840, p<0.025) and ALT (r=0.817, p<0.025) level. However, in chronic liver disease, there was no correlation between neopterin levels and liver function tests in chronic liver diseases. 3) According to Pugh`s classification, there was no significant differences between three groups, but urinary neopterin levels increased significantly in HCC than LC (p<0.001). Conclusions: Our data suggest that urinary neopterin level reflects cell mediated immunity and may be useful marker to predict the clinical course of the various chronic liver diseases.
고인습성 약물인 피리도스티그민의 마이크로캅셀화에 의한 분체 특성의 개선
김대석,김인화,정석재,심창구 한국약제학회 2002 Journal of Pharmaceutical Investigation Vol.32 No.1
The purpose of this study is to microencapsulate a highly hygroscopic drug, pyridostigmine bromide (PB), with a waterproof wall material, in order to increase the flowability of the drug particles. Polyvinylacetaldiethylaminoacetate (AEA), Eugragit E and Eugragit RS were examined as the wall materials. Microcapsules containing PB were prepared by the evaporation technique in an acetone/liquid paraffin system using aluminum tristearate as a core material, and evaluated for drug encapsulation efficiency, surface morphology, particle size and drug dissolution. The encapsulation of PB in the wall material was almost complete. Among the wall materials examined, AEA exhibited the most excellency in shape, surface texture, flowability, size distribution of microcapsules. Above results suggest that AEA would be a potential wall material for microcapsulation of highly hygroscopic drugs, such as PB. Through microencapsulation with AEA, inconvenience of handling of PB powders encountered in the process of weighing and packing the powders to tableting die or capsule body could be greatly improved.
위 출구 폐색을 초래하여 내시경적 절제술로 치료한 Brunner 선 과오종
김기홍,이옥재,심대석,정기문,장종억 대한내과학회 1998 대한내과학회지 Vol.54 No.1
Brunner's gland hamartomas are rare, benign duodenal tumors. But, they are the commonest hamartomas in the small intestine and believed to represent hyperplasia of Brunner's glands, perhaps in response to excessive gastric acid secretion. Brunner's gland hamartomas are usually smaller than 1cm and asymptomatic, incidental finding during endoscopy or radiographic examination. We report a case of large Brunner's gland hamartoma which prolapsed into gastric antrum and caused gastric outlet obstruction, and was resected by endoscopic polypectomy.
김건호,이옥재,신원호,심대석,류경렬,김건용,황일용 대한내과학회 1993 대한내과학회지 Vol.45 No.5
Secondary hemochromatosis is primarily a consequence of the treatment of the anemia of long term hemodialysis patients with frequent blood transfusions, seldom a result of oral or parentral iron therapy. Clinically, iron overload may be a serious problem for some maintenance hemadialysis patients and may be manifested by organ dysfunctions. Diagnosis of iron overload can be established by serum ferritin determination, liver biopsy or bone marrow examination, which correlates closely with total body iron stores. It is important to early detect the iron overload and to ristrict blood transfusions or iron therapy in these patients. We present secondary hemochromatosis in a long term hemodialysis patients with 140 pints blood transfusions for 5 years, confirmed by serum ferritin level, HLA (human leukocyte antigen) test and liver biopsy. We are treating this patient with recombinant human erythropoietin (EPO) in order to reduce the frequency of blood transfusions.